Two new studies led by researchers at Washington University School of Medicine in St. Louis have identified a possible way to block the progression of several forms of blood cancer using a drug ...

The investigational drug, called PMD-026, is currently in phase 2 clinical trials for the treatment of breast cancer.

Two new studies led by researchers at Washington University School of Medicine in St. Louis have identified a possible way to block the progression of several forms of blood cancer using a drug ...

LYT-200 now has gained fast track designation from the FDA in acute myeloid leukemia in addition to its prior designation for ...

Acute Myeloid Leukaemia (AML) with Retinoic acid receptor-gamma (RARG) fusions have similarities to Acute Promyelocytic Leukemia (APL) but are not responsive to standard APL treatments.

Environmental toxins like pesticides and heavy metals can lead to blood cancer. Learn how genetics, lifestyle, and exposure ...

1Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas.

A new study evaluating the quadratic phenotypic optimization platform shows it can accurately predict personalized drug ...

Vevoctadekin is under clinical development by Simcha Therapeutics and currently in Phase I for Refractory Acute Myeloid Leukemia.

Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic ...